Harrington William R, Sheng Shubin, Barnett Daniel H, Petz Larry N, Katzenellenbogen John A, Katzenellenbogen Benita S
Department of Molecular and Integrative Physiology, University of Illinois, 407 S Goodwin Avenue, 524 Burrill Hall, Urbana, IL 61801-3704, USA.
Mol Cell Endocrinol. 2003 Aug 29;206(1-2):13-22. doi: 10.1016/s0303-7207(03)00255-7.
Estrogens exert their regulatory transcriptional effects, which can be stimulatory or repressive, at diverse gene sites via two estrogen receptors, ERalpha and ERbeta. Since these two ERs have different tissue distributions, ligands that have the capacity to selectively activate or inhibit these two ERs would be useful in elucidating the biology of these two receptors and might assist in the development of estrogen pharmaceuticals with improved tissue selectivity. We have developed several ligands that showed ERalpha or ERbeta selectivity at promoter-gene sites containing consensus estrogen response elements (EREs): ERalpha-selective agonist (propyl-pyrazole-triol (PPT)), ERalpha-selective antagonist (methyl-piperidino-pyrazole (MPP)), ERbeta-potency selective agonist (diarylpropionitrile (DPN)) and ERbeta-selective antagonist/ERalpha-agonist (R,R-tetrahydrochrysene (R,R-THC)). In this study, we have examined the activity of these compounds at a range of gene sites where ER stimulates gene expression through non-consensus EREs (complement C3), or multiple half-EREs (NHE-RF/EBP50), or by tethering to DNA via other proteins (TGF beta3 and progesterone receptor A/AP-1), and at gene sites where ER represses gene transcription (interleukin-6). At all of these genes, PPT showed full stimulation through ERalpha while displaying no agonism through ERbeta. MPP antagonized estradiol actions on gene transactivation and transrepression through ERalpha, with little or no effect on transcription mediated through ERbeta. DPN displayed subtype-selective agonism, being ca. 30-fold more potent through ERbeta. R,R-THC was a complete antagonist through ERbeta and displayed agonism through ERalpha, the level of which was promoter dependent. Because these ligands maintain their agonist or antagonist character and ER subtype-selectivity at gene sites of diverse nature, where estradiol is either stimulatory or inhibitory, these compounds should prove useful in elucidating the biological functions of ERalpha and ERbeta.
雌激素通过两种雌激素受体ERα和ERβ在不同的基因位点发挥其调节转录的作用,这种作用可以是刺激性的,也可以是抑制性的。由于这两种雌激素受体具有不同的组织分布,能够选择性激活或抑制这两种受体的配体将有助于阐明这两种受体的生物学特性,并可能有助于开发具有更高组织选择性的雌激素药物。我们已经开发了几种在含有共有雌激素反应元件(ERE)的启动子-基因位点表现出ERα或ERβ选择性的配体:ERα选择性激动剂(丙基吡唑三醇(PPT))、ERα选择性拮抗剂(甲基哌啶基吡唑(MPP))、ERβ效价选择性激动剂(二芳基丙腈(DPN))和ERβ选择性拮抗剂/ERα激动剂(R,R-四氢 Chrysene(R,R-THC))。在本研究中,我们检测了这些化合物在一系列基因位点的活性,在这些位点,雌激素受体通过非共有ERE(补体C3)、多个半ERE(NHE-RF/EBP50)或通过与其他蛋白质结合到DNA(TGFβ3和孕激素受体A/AP-1)来刺激基因表达,以及在雌激素受体抑制基因转录的基因位点(白细胞介素-6)。在所有这些基因中,PPT通过ERα表现出完全的刺激作用,而通过ERβ则没有激动作用。MPP拮抗雌二醇对通过ERα的基因反式激活和反式抑制作用,对通过ERβ介导的转录几乎没有影响。DPN表现出亚型选择性激动作用,通过ERβ的效力约高30倍。R,R-THC通过ERβ是一种完全拮抗剂,通过ERα表现出激动作用,其水平取决于启动子。由于这些配体在不同性质的基因位点保持其激动剂或拮抗剂特性以及ER亚型选择性,在这些位点雌二醇要么具有刺激性要么具有抑制性,这些化合物应该有助于阐明ERα和ERβ的生物学功能。